{
    "ticker": "TBRG",
    "name": "Tobira Therapeutics, Inc.",
    "description": "Tobira Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative therapies for the treatment of liver diseases, particularly non-alcoholic steatohepatitis (NASH) and other chronic liver conditions. Founded in 2010, Tobira aims to address the significant unmet medical need in the realm of liver disease through its proprietary drug candidates and advanced research programs. The company's lead product candidates, including TB-403 and TB-500, are designed to improve liver function and reduce inflammation, thereby offering hope to millions affected by chronic liver diseases. Tobira is committed to advancing its clinical trials and research efforts to bring effective therapies to market. The company collaborates with leading research institutions and thought leaders in the field to enhance its understanding of liver diseases and develop targeted treatments. With a dedicated team of scientists and industry veterans, Tobira Therapeutics is poised to make significant contributions to liver health and overall patient care. The company\u2019s mission is to transform the lives of patients with liver diseases through innovative research and compassionate care.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "San Francisco, California, USA",
    "founded": "2010",
    "website": "https://www.tobiratherapeutics.com",
    "ceo": "Dr. William G. E. Smith",
    "social_media": {
        "twitter": "https://twitter.com/TobiraThera",
        "linkedin": "https://www.linkedin.com/company/tobira-therapeutics/"
    },
    "investor_relations": "https://www.tobiratherapeutics.com/investors",
    "key_executives": [
        {
            "name": "Dr. William G. E. Smith",
            "position": "CEO"
        },
        {
            "name": "Dr. Jane Doe",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "TB-403",
                "TB-500"
            ]
        }
    ],
    "seo": {
        "meta_title": "Tobira Therapeutics, Inc. | Innovative Therapies for Liver Diseases",
        "meta_description": "Explore Tobira Therapeutics, Inc., a biopharmaceutical company dedicated to developing innovative therapies for liver diseases like NASH.",
        "keywords": [
            "Tobira",
            "Liver Diseases",
            "NASH",
            "Biopharmaceuticals",
            "Chronic Liver Conditions"
        ]
    },
    "faq": [
        {
            "question": "What does Tobira Therapeutics focus on?",
            "answer": "Tobira Therapeutics focuses on developing therapies for liver diseases, particularly non-alcoholic steatohepatitis (NASH)."
        },
        {
            "question": "Who is the CEO of Tobira Therapeutics?",
            "answer": "Dr. William G. E. Smith is the CEO of Tobira Therapeutics, Inc."
        },
        {
            "question": "Where is Tobira Therapeutics headquartered?",
            "answer": "Tobira Therapeutics is headquartered in San Francisco, California, USA."
        },
        {
            "question": "What are Tobira's main product candidates?",
            "answer": "Tobira's main product candidates include TB-403 and TB-500."
        },
        {
            "question": "When was Tobira Therapeutics founded?",
            "answer": "Tobira Therapeutics was founded in 2010."
        }
    ],
    "competitors": [
        "GILD",
        "VRTX",
        "AMGN",
        "MRNA"
    ],
    "related_stocks": [
        "BMY",
        "JNJ",
        "PFE",
        "ABBV"
    ]
}